Max Fehlmann

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.

The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.

A French version of this release is available via CQDM’s website.

This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor

Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.

The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto.

Max Fehlmann

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Encycle investigators receive CQDM investment

Quick Links

Contact Us